Physical distancing versus testing with self-isolation for controlling an emerging epidemic.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
20 05 2023
Historique:
received: 02 07 2022
accepted: 12 05 2023
medline: 22 5 2023
pubmed: 21 5 2023
entrez: 20 5 2023
Statut: epublish

Résumé

Two distinct strategies for controlling an emerging epidemic are physical distancing and regular testing with self-isolation. These strategies are especially important before effective vaccines or treatments become widely available. The testing strategy has been promoted frequently but used less often than physical distancing to mitigate COVID-19. We compared the performance of these strategies in an integrated epidemiological and economic model that includes a simple representation of transmission by "superspreading," wherein a relatively small fraction of infected individuals cause a large share of infections. We examined the economic benefits of distancing and testing over a wide range of conditions, including variations in the transmissibility and lethality of the disease meant to encompass the most prominent variants of COVID-19 encountered so far. In a head-to-head comparison using our primary parameter values, both with and without superspreading and a declining marginal value of mortality risk reductions, an optimized testing strategy outperformed an optimized distancing strategy. In a Monte Carlo uncertainty analysis, an optimized policy that combined the two strategies performed better than either one alone in more than 25% of random parameter draws. Insofar as diagnostic tests are sensitive to viral loads, and individuals with high viral loads are more likely to contribute to superspreading events, superspreading enhances the relative performance of testing over distancing in our model. Both strategies performed best at moderate levels of transmissibility, somewhat lower than the transmissibility of the ancestral strain of SARS-CoV-2.

Identifiants

pubmed: 37210388
doi: 10.1038/s41598-023-35083-x
pii: 10.1038/s41598-023-35083-x
pmc: PMC10199672
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

8185

Informations de copyright

© 2023. The Author(s).

Références

Int J Infect Dis. 2011 Aug;15(8):e510-3
pubmed: 21737332
Lancet Child Adolesc Health. 2020 Nov;4(11):817-827
pubmed: 32758453
Virulence. 2021 Dec;12(1):2013-2016
pubmed: 34320912
Elife. 2021 Feb 23;10:
pubmed: 33620317
J Med Virol. 2021 Oct;93(10):5783-5788
pubmed: 34050945
Elife. 2021 Nov 08;10:
pubmed: 34747698
Int J Infect Dis. 2021 Dec;113:43-46
pubmed: 34628024
Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):338-42
pubmed: 8990210
Ecohealth. 2014 Dec;11(4):464-75
pubmed: 25233829
Infect Dis Model. 2020 Nov 30;6:148-168
pubmed: 33474518
JAMA Netw Open. 2021 Aug 2;4(8):e2126931
pubmed: 34448871
Proc Biol Sci. 2015 Nov 7;282(1818):20150814
pubmed: 26511046
Risk Anal. 2021 May;41(5):761-770
pubmed: 32677076
QJM. 2020 May 1;113(5):311-312
pubmed: 32227218
Ecohealth. 2021 Mar;18(1):44-60
pubmed: 34086129
BMJ Open. 2020 Aug 5;10(8):e039856
pubmed: 32759252
Cochrane Database Syst Rev. 2021 Mar 24;3:CD013705
pubmed: 33760236
J Infect Chemother. 2021 Apr;27(4):613-616
pubmed: 33423918
Health Sci Rep. 2021 May 03;4(2):e274
pubmed: 33977156
Wellcome Open Res. 2020 Apr 9;5:67
pubmed: 32685698
Lancet Glob Health. 2020 Apr;8(4):e488-e496
pubmed: 32119825
Lancet. 2020 Mar 14;395(10227):e47
pubmed: 32113505
Nature. 2005 Nov 17;438(7066):355-9
pubmed: 16292310
J Public Econ. 2020 Dec;192:104316
pubmed: 33162621
Clin Infect Dis. 2021 Nov 2;73(9):e2918-e2920
pubmed: 33009802
Nat Hum Behav. 2021 Nov;5(11):1519-1527
pubmed: 34646034
J Infect Dis. 2021 May 20;223(9):1528-1537
pubmed: 33585934
Nature. 2020 Aug;584(7820):175-176
pubmed: 32770149
Elife. 2021 Aug 24;10:
pubmed: 34425938
Int J Infect Dis. 2020 Dec;101:138-148
pubmed: 33007452
JAMA Netw Open. 2020 Jul 1;3(7):e2016818
pubmed: 32735339
J Clin Virol. 2021 Apr;137:104782
pubmed: 33711691
Nat Med. 2020 Jun;26(6):855-860
pubmed: 32322102
Am J Infect Control. 2021 Jan;49(1):21-29
pubmed: 32659413
PLoS One. 2021 Jun 9;16(6):e0252373
pubmed: 34106993
Phys Rev Lett. 2021 Mar 19;126(11):118301
pubmed: 33798363
J Travel Med. 2020 Mar 13;27(2):
pubmed: 32052846
BMJ. 2021 Mar 31;372:n608
pubmed: 33789843
Environ Resour Econ (Dordr). 2020;76(4):705-729
pubmed: 32836854
Eur J Epidemiol. 2020 Dec;35(12):1123-1138
pubmed: 33289900
BMJ. 2022 Feb 16;376:e068993
pubmed: 35172971
BMJ. 2020 Jul 1;370:m2516
pubmed: 32611558
J Risk Uncertain. 2020;61(2):129-154
pubmed: 33199940
Ann Intern Med. 2021 Apr;174(4):472-483
pubmed: 33347322
Sensors (Basel). 2021 Oct 01;21(19):
pubmed: 34640901
iScience. 2020 Aug 21;23(8):101406
pubmed: 32771976
EClinicalMedicine. 2020 Apr 11;21:100348
pubmed: 32292900
Sao Paulo Med J. 2021 Mar-Apr;139(2):163-169
pubmed: 33605305
CMAJ. 2020 May 11;192(19):E497-E505
pubmed: 32269018
J Travel Med. 2021 Oct 11;28(7):
pubmed: 34369565
BMJ. 2020 Mar 22;368:m1163
pubmed: 32201376
JAMA. 2022 Jan 18;327(3):213-214
pubmed: 34989785

Auteurs

Stephen C Newbold (SC)

Department of Economics, University of Wyoming, Laramie, WY, 82071, USA. snewbold@uwyo.edu.

Madison Ashworth (M)

Department of Economics, University of Wyoming, Laramie, WY, 82071, USA.
Fletcher Group, Inc., London, KY, 40741, USA.

David Finnoff (D)

Department of Economics, University of Wyoming, Laramie, WY, 82071, USA.

Jason F Shogren (JF)

Department of Economics, University of Wyoming, Laramie, WY, 82071, USA.

Linda Thunström (L)

Department of Economics, University of Wyoming, Laramie, WY, 82071, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH